There are currently 1018 clinical trials in Aurora, Colorado looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Hospital Colorado, University of Colorado, University of Colorado Hospital and University of Colorado - Denver. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Advancing Rehabilitation Paradigms for Older Adults in Skilled Nursing Facilities
NCT05492240
Recruiting
This cluster randomized clinical trial seeks to provide large-scale, foundational evidence that high-intensity rehabilitation is effective and can be systematically implemented to improve functional outcomes for patients admitted to skilled nursing facilities following hospitalization. Additionally, this study will generate a descriptive overview of factors that predict implementation success while informing effective implementation strategies for future skilled nursing facilities innovation.
Gender:
ALL
Ages:
Between 50 years and 120 years
Trial Updated:
07/03/2025
Locations: University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
Conditions: Aging, Functional Recovery, Skilled Nursing Facility, Medically Complex, Deconditioning
Register for Updates
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
NCT06430541
Recruiting
The goal of this clinical trial is to test whether psilocybin along with therapy in women with early breast cancer and ovarian cancer in remission can improve their fear of recurrence. The main question\[s\] it aims to answer \[is/are\]: Does psilocybin assisted therapy improve fear of cancer recurrence? Does psilocybin assisted therapy improve anxiety, depression, and quality of life? Participants will complete a series of survey measures, participate in preparatory therapy. After prep therap... Read More
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
07/03/2025
Locations: Outpatient CTRC, Aurora, Colorado +1 locations
Conditions: Breast Cancer, Ovarian Cancer
Register for Updates
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
NCT06559189
Recruiting
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
Gender:
ALL
Ages:
Between 3 months and 30 years
Trial Updated:
07/03/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors
NCT05073848
Recruiting
This is an investigation of possible relationships between daily physical activity (PA) and different measurements of fatigue in cancer survivors participating in a cancer exercise program.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Cancer Remission
Register for Updates
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05267821
Recruiting
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Gender:
ALL
Ages:
Between 1 day and 17 years
Trial Updated:
07/02/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Register for Updates
Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
NCT06141031
Recruiting
To evaluate the safety and tolerability of TTI-101 given in combination with Stereotactic Body Radiation Therapy (SBRT) in borderline resectable and locally advanced pancreatic ductal adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Colorado, Aurora, Colorado
Conditions: Pancreatic Cancer
Register for Updates
CLEANer Aspiration for Pulmonary Embolism
NCT06189313
Recruiting
To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
Register for Updates
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT06919666
Recruiting
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Universtiy of Colorado Hospital, Aurora, Colorado
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399
Recruiting
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/01/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Aurora, Colorado
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer
NCT06145750
Recruiting
The purpose of this study is to determine whether availability of DNA Evaluation of Fragments for Early Interception (DELFI) Lung Cancer Screening Test, FirstLook™ to practicing physicians affects overall lung cancer screening rates among their patients who are recommended and eligible for screening based on 2021 United States Preventive Services Task Force (USPSTF) but are not up to date with it. DELFI hypothesized that patients in the care of physicians or practice groups who have FirstLook™ w... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/01/2025
Locations: DARTNet Institute, Aurora, Colorado
Conditions: Lung Cancer
Register for Updates
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
NCT06430385
Recruiting
The primary purpose of this study is to evaluate the safety and tolerability of ION440.
Gender:
MALE
Ages:
Between 2 years and 65 years
Trial Updated:
07/01/2025
Locations: University of Colorado Hopsital - Anschutz Medical Campus, Aurora, Colorado
Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Register for Updates